KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target

HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis

(2020) Patrick P. C. Boor et al.   BRITISH JOURNAL OF CANCER

B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling

(2020) Sadiye Amcaoglu Rieder et al.   Cellular & Molecular Immunology

HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma

(2020) Qiang-Hua Zhou et al.   Journal for ImmunoTherapy of Cancer

Sestrins induce natural killer function in senescent-like CD8+ T cells

(2020) Branca I. Pereira et al.   NATURE IMMUNOLOGY

Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma

(2020) Zhen Zhang et al.   Frontiers in Cell and Developmental Biology

The Immunoglobulin Superfamily Receptome Defines Cancer-Relevant Networks Associated with Clinical Outcome

(2020) Erik Verschueren et al.   CELL

A Human IgSF Cell-Surface Interactome Reveals a Complex Network of Protein-Protein Interactions

(2020) Woj M. Wojtowicz et al.   CELL

KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

(2020) Rupal S. Bhatt et al.   Cancer Immunology Research

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1

(2019) Chu-Yu Jing et al.   Journal for ImmunoTherapy of Cancer

The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma

(2019) Yao Xiao et al.   DISEASE MARKERS

Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells

(2019) Takahiro Kamiya et al.   JOURNAL OF CLINICAL INVESTIGATION

CD28 homolog is a strong activator of natural killer cells for lysis of B7H7+ tumor cells

(2019) Xiaoxuan Zhuang et al.   Cancer Immunology Research

HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer

(2019) Li Wei et al.   Human Cell

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

(2019) Yunlong Zhao et al.   IMMUNITY

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1–Negative Human Lung Cancers

(2018) Haiying Cheng et al.   CLINICAL CANCER RESEARCH

Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target

(2018) Dongming Chen et al.   JOURNAL OF MEDICAL GENETICS

Inhibitory and Coactivating Receptors Recognising the Same Ligand: Immune Homeostasis Exploited by Pathogens and Tumours

(2018) Francesca Levi-Schaffer et al.   TRENDS IN IMMUNOLOGY

Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma

(2018) Ziwen Zhu et al.   OncoTargets and Therapy

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

(2018) S. N. Gettinger et al.   Nature Communications

HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival

(2018) Han Yan et al.   CANCER LETTERS

The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3

(2017) Murali Janakiram et al.   IMMUNOLOGICAL REVIEWS

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status

(2016) Haiying Cheng et al.   CLINICAL CANCER RESEARCH

Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer and T-cell biology

(2016) Vivien Béziat et al.   IMMUNOLOGY

KEGG: new perspectives on genomes, pathways, diseases and drugs

(2016) Minoru Kanehisa et al.   NUCLEIC ACIDS RESEARCH

HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival

(2016) Pratistha Koirala et al.   Scientific Reports

Cancer immunotherapy: harnessing the immune system to battle cancer

(2015) Yiping Yang   JOURNAL OF CLINICAL INVESTIGATION

Human Leukocyte Antigen E Contributes to Protect Tumor Cells from Lysis by Natural Killer Cells

(2015) Elisa Lo Monaco et al.   NEOPLASIA

HTSeq--a Python framework to work with high-throughput sequencing data

(2014) S. Anders et al.   BIOINFORMATICS

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

(2014) M. Janakiram et al.   CLINICAL CANCER RESEARCH

MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells

(2013) P. Leone et al.   JNCI-Journal of the National Cancer Institute

HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

(2013) R. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

B7-H5 costimulates human T cells via CD28H

(2013) Yuwen Zhu et al.   Nature Communications

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

Multiple distinct NK-cell synapses

(2011) E. M. Mace et al.   BLOOD

Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B

(2011) Julian P. Vivian et al.   NATURE

Dissecting CD56dim human NK cells

(2010) L. Moretta   BLOOD

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

Lentiviral Transduction of Mammary Stem Cells for Analysis of Gene Function during Development and Cancer

(2008) Bryan E. Welm et al.   Cell Stem Cell

Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future

(2008) Marc Daëron et al.   IMMUNOLOGICAL REVIEWS